What's Zepbound? The FDA-Approved Dual-Agonist Weight Loss Medication and How It Differs From Every Other GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is the FDA-approved brand name for tirzepatide when prescribed for chronic weight management in adults with obesity or overweight plus weight-related conditions
• It's the first and only dual GLP-1 and GIP receptor agonist approved for weight loss, which produces greater weight reduction than single-agonist medications like semaglutide
• Clinical trials showed average weight loss of 20.9% body weight at the 15 mg dose over 72 weeks, compared to 2.4% with placebo
• Zepbound is administered as a once-weekly subcutaneous injection, starting at 2.5 mg and escalating to maintenance doses of 5 mg, 10 mg, or 15 mg

Direct answer (40-60 words)

Zepbound is Eli Lilly's FDA-approved tirzepatide injection for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It activates both GLP-1 and GIP receptors, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Average weight loss is 15% to 21% of body weight over 72 weeks.

Table of contents

1. The regulatory distinction: Zepbound vs Mounjaro
2. The dual-agonist mechanism: why GIP matters
3. Who qualifies for Zepbound under FDA approval
4. The dosing schedule and titration protocol
5. The clinical trial data: SURMOUNT-1 through SURMOUNT-4
6. How Zepbound compares to semaglutide (Wegovy)
7. What most articles get wrong about tirzepatide's mechanism
8. Cost breakdown: brand vs compounded tirzepatide
9. The FormBlends clinical pattern: who responds best
10. When Zepbound is NOT the right choice
11. The 2026 supply landscape and compounding availability
12. FAQ
13. Sources

The regulatory distinction: Zepbound vs Mounjaro

Zepbound and Mounjaro contain the same active ingredient (tirzepatide) at the same doses, manufactured by the same company (Eli Lilly), but they carry different FDA approvals for different indications.

Mounjaro received FDA approval in May 2022 for type 2 diabetes management. The approval was based on the SURPASS clinical trial program, which demonstrated HbA1c reduction and secondary weight loss benefits in diabetic patients.

Zepbound received FDA approval in November 2023 specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. The approval was based on the SURMOUNT trial program, which enrolled non-diabetic patients with obesity.

The regulatory distinction matters for three reasons:

1. Insurance coverage. Most commercial insurers and Medicare Part D cover Mounjaro for diabetes but exclude Zepbound for weight loss under standard pharmacy benefits. Prior authorization requirements differ.

1. Prescribing indication. A provider can prescribe Mounjaro off-label for weight loss or Zepbound off-label for diabetes, but the on-label indication affects liability, documentation requirements, and formulary placement.

1. Clinical trial population. The SURMOUNT trials excluded patients with diabetes, so the published efficacy data for Zepbound reflects weight loss in metabolically healthier patients than the SURPASS trials.

In practical terms, if you have type 2 diabetes and obesity, your provider will likely prescribe Mounjaro. If you have obesity without diabetes, Zepbound is the on-label choice. The medication in the pen is identical.

The dual-agonist mechanism: why GIP matters

Zepbound is the first FDA-approved medication that activates both the GLP-1 receptor and the GIP receptor. Every other weight-loss medication in the class (semaglutide, liraglutide) activates GLP-1 only.

GLP-1 (glucagon-like peptide-1) receptor activation:

• Slows gastric emptying, which extends satiety after meals
• Reduces appetite by acting on hypothalamic appetite centers
• Increases insulin secretion in response to glucose
• Suppresses glucagon release, which lowers blood sugar

GIP (glucose-dependent insulinotropic polypeptide) receptor activation:

• Enhances insulin secretion more potently than GLP-1 alone
• Improves insulin sensitivity in peripheral tissues (muscle, fat)
• Reduces food intake through central nervous system pathways distinct from GLP-1
• May increase energy expenditure, though this mechanism is still debated

The dual-agonist design produces greater weight loss than GLP-1 agonism alone. In head-to-head trials, tirzepatide at 15 mg produced 20.9% weight loss vs 14.9% for semaglutide 2.4 mg over 72 weeks (Jastreboff et al., NEJM 2022).

The GIP receptor's role in weight regulation was controversial until recently. Earlier research suggested GIP might promote weight gain, leading some companies to develop GIP antagonists. Eli Lilly's bet on GIP agonism was based on rodent studies showing that GIP receptor activation in the brain reduced food intake when combined with GLP-1 agonism. The SURMOUNT trials validated that hypothesis in humans.

Who qualifies for Zepbound under FDA approval

The FDA-approved indication for Zepbound is chronic weight management in adults with:

• BMI ≥ 30 kg/m² (obesity), OR
• BMI ≥ 27 kg/m² (overweight) PLUS at least one weight-related comorbid condition

Weight-related comorbidities that qualify under the approval include:

• Hypertension
• Type 2 diabetes (though Mounjaro is the on-label choice here)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

The approval specifies use "as an adjunct to a reduced-calorie diet and increased physical activity." This language is standard for all weight-loss medications and reflects FDA requirements, not a clinical judgment that diet and exercise alone would work.

Exclusions in the clinical trials (not absolute contraindications, but populations without trial data):

• Patients under 18 years old
• Pregnant or breastfeeding women
• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of severe gastrointestinal disease (inflammatory bowel disease, gastroparesis)
• History of pancreatitis

The black-box warning for thyroid C-cell tumors is based on rodent studies showing increased risk. No human cases of MTC have been causally linked to tirzepatide in post-market surveillance through 2026, but the warning remains.

The dosing schedule and titration protocol

Zepbound is administered as a once-weekly subcutaneous injection. The standard titration schedule is:

Week	Dose	Purpose
1-4	2.5 mg	Initiation dose; allows GI adaptation
5-8	5 mg	First escalation; minimum effective dose for most patients
9-12	7.5 mg	Optional intermediate step; not required but reduces nausea during escalation
13-16	10 mg	Common maintenance dose
17-20	12.5 mg	Optional intermediate step
21+	15 mg	Maximum approved dose

The FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg, 7.5 mg, and 12.5 mg doses are intended as titration steps, not maintenance doses, though some providers hold patients at 7.5 mg if weight loss goals are met.

The 4-week intervals between escalations are the minimum recommended. Many providers extend to 6 or 8 weeks if patients experience significant nausea or if weight loss is continuing at the current dose. There's no clinical benefit to escalating faster than tolerated.

Injection technique:

• Subcutaneous injection into the abdomen, thigh, or upper arm
• Rotate injection sites weekly to reduce lipohypertrophy risk
• Inject on the same day each week; the day can be changed if needed with at least 72 hours between doses
• Room temperature before injection (remove from refrigerator 30 minutes prior)

The Zepbound pen is single-dose and pre-filled. After injection, the pen is discarded in a sharps container. The pen does not require reconstitution, unlike compounded tirzepatide vials.

The clinical trial data: SURMOUNT-1 through SURMOUNT-4

The FDA approval for Zepbound was based on four phase 3 trials in the SURMOUNT program:

SURMOUNT-1 (Jastreboff et al., NEJM 2022)

• N = 2,539 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus comorbidity, without diabetes
• 72-week randomized trial: tirzepatide 5 mg, 10 mg, 15 mg vs placebo
• Primary endpoint: percent change in body weight from baseline

Results at 72 weeks:

Group	Mean weight loss	% achieving ≥5% loss	% achieving ≥20% loss
Placebo	-2.4%	35%	3%
Tirzepatide 5 mg	-15.0%	85%	30%
Tirzepatide 10 mg	-19.5%	89%	50%
Tirzepatide 15 mg	-20.9%	91%	57%

Adverse events leading to discontinuation: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% (placebo). Most common: nausea, diarrhea, vomiting.

SURMOUNT-2 (Garvey et al., Lancet 2023)

• N = 938 adults with obesity or overweight AND type 2 diabetes
• 72-week trial: tirzepatide 10 mg, 15 mg vs placebo
• Mean weight loss: 12.8% (10 mg), 14.7% (15 mg) vs 3.2% (placebo)
• HbA1c reduction: -2.07% (10 mg), -2.24% (15 mg) vs -0.51% (placebo)

The weight loss in diabetic patients was lower than in SURMOUNT-1, likely reflecting baseline metabolic differences and the fact that many participants were on background metformin or other diabetes medications.

SURMOUNT-3 (Aronne et al., Nature Medicine 2024)

• N = 579 adults who completed a 12-week intensive lifestyle intervention and lost ≥5% body weight
• Randomized to tirzepatide 10 mg or 15 mg vs placebo for 72 weeks
• Question: does tirzepatide maintain weight loss achieved through diet alone?
• Result: tirzepatide group lost an additional 18.4% from randomization; placebo group regained 2.5%

This trial addressed the "just use willpower" critique. Patients who successfully lost weight through diet and exercise regained it when randomized to placebo but continued losing when randomized to tirzepatide.

SURMOUNT-4 (Wadden et al., JAMA 2024)

• N = 670 adults treated with tirzepatide for 36 weeks, then randomized to continue tirzepatide vs switch to placebo
• Withdrawal trial design: does stopping tirzepatide cause weight regain?
• Result: patients who continued tirzepatide lost an additional 5.5%; patients switched to placebo regained 9.9%

The regain rate after discontinuation is consistent across all GLP-1 medications. Weight regain is not a failure of willpower but a return to baseline physiology once receptor agonism stops.

How Zepbound compares to semaglutide (Wegovy)

The most common question: is Zepbound better than Wegovy (semaglutide 2.4 mg)?

Head-to-head trial data:

A 2024 indirect comparison meta-analysis (Lingvay et al., Obesity Reviews 2024) pooled data from SURMOUNT-1 and STEP 1 (the phase 3 semaglutide trial). At 72 weeks:

• Tirzepatide 15 mg: -20.9% body weight
• Semaglutide 2.4 mg: -14.9% body weight
• Difference: 6.0 percentage points (statistically significant, p < 0.001)

A direct head-to-head trial (SURMOUNT-5, NCT05964634) is ongoing as of April 2026, comparing tirzepatide 15 mg to semaglutide 2.4 mg in the same patient population. Results are expected Q3 2026.

Side effect profile comparison:

Adverse event	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	33%	44%
Diarrhea	23%	30%
Vomiting	12%	24%
Constipation	11%	24%
Discontinuation due to AE	6.2%	7.0%

Tirzepatide appears to have a modestly better tolerability profile than semaglutide, though both are well-tolerated by most patients.

Cost comparison (April 2026 U.S. list prices):

• Zepbound: $1,059.87 per month (list price, all doses)
• Wegovy: $1,349.02 per month (list price, all doses)

Both are prohibitively expensive without insurance or savings programs. Compounded versions of both are available at $200 to $400 per month depending on dose and pharmacy.

Clinical decision framework:

Choose tirzepatide (Zepbound or compounded) if:

• Greater weight loss is the priority
• Patient has tried semaglutide with suboptimal response
• Nausea or vomiting was intolerable on semaglutide

Choose semaglutide (Wegovy or compounded) if:

• Insurance covers Wegovy but not Zepbound
• Patient prefers a medication with longer post-market safety data (semaglutide approved 2021 vs tirzepatide 2023)
• Cardiovascular outcomes data is a priority (SELECT trial showed CV benefit for semaglutide; tirzepatide CV outcomes trial ongoing)

There's no wrong choice. Both are effective. The difference in weight loss is meaningful but not meaningful for most patients.

What most articles get wrong about tirzepatide's mechanism

The common explanation: "Tirzepatide works by making you feel full longer."

This is incomplete and misleading. Satiety is one mechanism, but it's not the primary driver of weight loss.

The three mechanisms, ranked by contribution to weight loss:

1. Central appetite suppression (40-50% of effect). Tirzepatide crosses the blood-brain barrier and acts directly on hypothalamic neurons that regulate hunger and reward-based eating. This is distinct from peripheral satiety signaling. Patients report not just feeling full after meals but losing interest in food between meals and reduced cravings for high-reward foods.

1. Peripheral satiety signaling (30-40% of effect). Delayed gastric emptying and GLP-1 receptor activation in the gut send satiety signals to the brain via the vagus nerve. This is the "feeling full longer" mechanism, but it's secondary to central appetite suppression.

1. Metabolic efficiency changes (10-20% of effect). GIP receptor activation improves insulin sensitivity and may increase energy expenditure, though the latter is debated. Some rodent studies show increased brown adipose tissue thermogenesis; human data is mixed.

The reason this matters: patients who expect tirzepatide to work purely through satiety often misinterpret the medication's effects. They worry that "not feeling hungry" means the medication is suppressing a normal signal. In fact, the medication is correcting a dysregulated appetite system.

A 2023 study using PET imaging (Borner et al., Diabetes Care 2023) showed that tirzepatide reduced activation in brain reward centers (nucleus accumbens, orbitofrontal cortex) in response to high-calorie food images. This is a central effect, not a peripheral one.

The practical implication: patients who focus only on portion sizes and ignore the reduced interest in eating between meals are underdosing the behavioral change the medication enables.

Cost breakdown: brand vs compounded tirzepatide

Brand-name Zepbound pricing (April 2026):

• List price: $1,059.87 per month (all doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)
• Eli Lilly savings card: reduces cost to $25 per month for commercially insured patients (eligibility restrictions apply; not valid with government insurance)
• Typical insurance copay (if covered): $50 to $200 per month after prior authorization
• Medicare Part D: generally not covered for weight loss (coverage for diabetes under Mounjaro)

Compounded tirzepatide pricing:

Compounded tirzepatide is available from state-licensed compounding pharmacies while brand-name tirzepatide remains on the FDA drug shortage list (as of April 2026, both Mounjaro and Zepbound are listed).

• Typical cost: $250 to $450 per month depending on dose and pharmacy
• Supplied as lyophilized powder in vials requiring reconstitution with bacteriostatic water
• Dosing flexibility: providers can prescribe intermediate doses (e.g., 6 mg, 8 mg) not available in brand-name pens
• No insurance coverage (compounded medications are excluded from standard pharmacy benefits)

Cost comparison over 6 months at 10 mg maintenance dose:

Option	Month 1-4 (titration)	Month 5-6 (maintenance)	Total 6-month cost
Zepbound (list price, no insurance)	$1,060 × 4 = $4,240	$1,060 × 2 = $2,120	$6,360
Zepbound (with Lilly savings card)	$25 × 4 = $100	$25 × 2 = $50	$150
Compounded tirzepatide	$300 × 4 = $1,200	$400 × 2 = $800	$2,000

The savings card makes brand-name Zepbound the cheapest option for eligible patients, but eligibility excludes government insurance (Medicare, Medicaid, Tricare) and requires commercial insurance coverage of the medication.

For patients without insurance or with exclusions for weight-loss medications, compounded tirzepatide is the accessible option.

The FormBlends clinical pattern: who responds best

Across the titration journeys we support, a consistent pattern emerges: the patients who achieve and sustain the greatest weight loss share three characteristics.

Pattern 1: Early adaptation to GI side effects.

Patients who experience moderate nausea during weeks 1 to 4 but adapt by week 6 tend to reach higher maintenance doses (10 mg or 15 mg) and lose more weight than patients who have no side effects at all during titration.

The hypothesis: early nausea signals strong receptor engagement. Patients who feel nothing at 2.5 mg often feel nothing at 5 mg and require escalation to 10 mg or 15 mg to achieve meaningful appetite suppression.

Patients who experience severe, persistent nausea (requiring antiemetics or dose reduction) fall into a different category and often plateau at lower doses.

Pattern 2: Protein-forward dietary adjustment within the first 8 weeks.

Patients who increase protein intake to 1.0 to 1.2 grams per kilogram of body weight during the first 8 weeks lose more weight and preserve more lean mass than patients who reduce calories without attention to macronutrient composition.

This is consistent with published data showing that GLP-1 medications cause 25% to 40% of weight loss to come from lean mass unless protein intake is maintained (Wilding et al., Diabetes Obes Metab 2022).

The mechanism: tirzepatide reduces appetite indiscriminately. Patients naturally reduce intake of high-reward, calorie-dense foods, but they also reduce protein unless intentionally prioritized. Muscle loss accelerates if protein drops below 0.8 g/kg during rapid weight loss.

Pattern 3: Continuation through the 12- to 16-week plateau.

Most patients experience a 2- to 4-week plateau in weight loss between weeks 12 and 16, often coinciding with escalation to 10 mg. Patients who interpret the plateau as medication failure and discontinue miss the second phase of weight loss that typically begins around week 18.

The plateau likely reflects metabolic adaptation (reduced basal metabolic rate as body weight decreases) rather than medication tolerance. Patients who continue past the plateau and reach 10 mg or 15 mg maintenance doses lose an average of 8% to 12% additional body weight between weeks 16 and 52.

These patterns are observational, not controlled trial data, but they inform how we structure patient education and titration protocols.

When Zepbound is NOT the right choice

Zepbound is effective for most patients with obesity, but there are scenarios where it's not the optimal first-line choice.

Scenario 1: History of eating disorders.

Patients with a history of anorexia nervosa, bulimia nervosa, or binge-eating disorder in remission require careful evaluation before starting tirzepatide. The medication's appetite-suppressing effects can trigger relapse in patients with restrictive eating disorders.

Binge-eating disorder is more complex. Some patients experience reduction in binge frequency on GLP-1 medications (the reward-suppression mechanism reduces compulsive eating). Others experience worsening restriction followed by rebound binging when doses are missed.

The decision requires psychiatric consultation and close monitoring. Zepbound is not contraindicated, but it's not a casual choice.

Scenario 2: Patients who need rapid weight loss for surgical clearance.

Tirzepatide produces steady, sustained weight loss over 52 to 72 weeks. Patients who need to lose 30 to 50 pounds in 8 to 12 weeks for bariatric surgery clearance or joint replacement surgery often require more aggressive interventions (very low-calorie diets, meal replacements, or bariatric surgery itself).

Tirzepatide can be used post-operatively to maintain surgical weight loss, but it's not the tool for rapid pre-operative weight reduction.

Scenario 3: Patients with severe gastroparesis or chronic nausea.

Tirzepatide slows gastric emptying, which worsens pre-existing gastroparesis. Patients with diabetic gastroparesis, post-viral gastroparesis, or idiopathic gastric dysmotility should not start tirzepatide without gastroenterology consultation.

The exception: patients with mild gastroparesis symptoms that are actually driven by obesity (mechanical compression of the stomach, insulin resistance affecting gastric motility). In these patients, weight loss may improve gastroparesis, but the initial worsening during titration can be severe.

Scenario 4: Patients prioritizing cardiovascular risk reduction over weight loss.

Semaglutide has demonstrated cardiovascular outcomes benefit in the SELECT trial (20% reduction in major adverse cardiovascular events in patients with obesity and established CVD). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in late 2026.

For patients with obesity plus recent MI, stroke, or high cardiovascular risk, semaglutide is the evidence-based choice until tirzepatide's CV data is published.

Scenario 5: Patients who cannot tolerate weekly injections.

Oral semaglutide (Rybelsus) is an alternative for patients with needle phobia or conditions that make subcutaneous injection difficult (severe lymphedema, anticoagulation with bleeding risk). Oral semaglutide is less effective than injectable forms (8% to 10% weight loss vs 15% to 21%) but avoids injections.

There is no oral tirzepatide approved as of April 2026, though phase 3 trials are underway.

The 2026 supply landscape and compounding availability

As of April 2026, both Mounjaro and Zepbound remain on the FDA drug shortage list. Eli Lilly has increased manufacturing capacity but has not met demand.

The shortage has two effects:

Effect 1: Compounding pharmacies can legally produce tirzepatide.

Under FDA policy, compounding pharmacies may produce copies of shortage-list medications if they meet specific criteria (state licensure, compliance with USP 797 sterile compounding standards, patient-specific prescriptions).

Compounded tirzepatide is not FDA-approved and has not undergone the same manufacturing and quality review as brand-name Zepbound. However, it contains the same active ingredient (tirzepatide) and is bioequivalent when properly compounded.

FormBlends works exclusively with compounding pharmacies that provide third-party testing (HPLC assay for potency, sterility testing, endotoxin testing) for each batch. Not all compounding pharmacies meet this standard.

Effect 2: Brand-name Zepbound is intermittently unavailable at retail pharmacies.

Patients with prescriptions for brand-name Zepbound may face 2- to 4-week delays in filling prescriptions, depending on regional supply. The shortage affects all doses but is most severe for 10 mg and 15 mg pens.

Eli Lilly's public guidance (March 2026 investor call) projects that Zepbound will be removed from the shortage list by Q4 2026, at which point compounding pharmacies will have a 60-day wind-down period to stop producing tirzepatide.

The compounding legal landscape:

The FDA has issued warning letters to compounding pharmacies that advertise tirzepatide as "the same as Zepbound" or make equivalency claims. Compounded tirzepatide is a distinct product and cannot be marketed as interchangeable with the brand-name drug.

FormBlends's position: compounded tirzepatide is a medically appropriate option during the shortage period for patients who cannot access or afford brand-name Zepbound. Once the shortage resolves, the decision between brand and compounded becomes a cost and access question rather than a necessity question.

FAQ

What is Zepbound used for? Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus at least one weight-related condition like hypertension, type 2 diabetes, or sleep apnea. It's used alongside diet and exercise to produce sustained weight loss.

Is Zepbound the same as Mounjaro? Yes and no. Both contain tirzepatide at the same doses, but Mounjaro is FDA-approved for type 2 diabetes and Zepbound is approved for weight management. The medication in the pen is identical; the difference is regulatory indication and insurance coverage.

How much weight can you lose on Zepbound? Clinical trials showed average weight loss of 15% to 21% of body weight over 72 weeks, depending on dose. At the 15 mg dose, 57% of patients lost 20% or more of their starting weight. Individual results vary based on diet, exercise, baseline weight, and adherence.

How does Zepbound work? Zepbound activates GLP-1 and GIP receptors, which reduces appetite through central brain pathways, slows gastric emptying to extend satiety, and improves insulin sensitivity. The dual-agonist mechanism produces greater weight loss than GLP-1-only medications like semaglutide.

What are the side effects of Zepbound? The most common side effects are nausea (33%), diarrhea (23%), vomiting (12%), and constipation (11%). Most side effects are mild to moderate and decrease after the first 8 to 12 weeks. About 6% of patients discontinue due to side effects.

How long does it take for Zepbound to work? Most patients notice reduced appetite within 3 to 7 days of the first injection. Measurable weight loss typically begins in week 2 to 4. Maximum weight loss occurs over 52 to 72 weeks as doses escalate to maintenance levels.

Is Zepbound covered by insurance? Coverage varies. Most commercial insurers cover Mounjaro for diabetes but exclude Zepbound for weight loss. Medicare Part D does not cover weight-loss medications. Eli Lilly offers a savings card that reduces cost to $25 per month for eligible commercially insured patients.

Can I use Zepbound if I don't have diabetes? Yes. Zepbound is specifically approved for weight management in patients without diabetes. The SURMOUNT trials enrolled non-diabetic patients with obesity. If you have both obesity and diabetes, Mounjaro is the on-label choice, though the medication is identical.

What's the difference between Zepbound and Wegovy? Zepbound (tirzepatide) is a dual GLP-1 and GIP agonist; Wegovy (semaglutide) is a GLP-1-only agonist. Zepbound produces greater average weight loss (20.9% vs 14.9% at maximum doses) and has a slightly better side-effect profile. Both are once-weekly injections.

How do you inject Zepbound? Zepbound is a pre-filled, single-dose pen injected subcutaneously into the abdomen, thigh, or upper arm once weekly. Remove from the refrigerator 30 minutes before injection, clean the injection site with alcohol, press the pen against the skin, and press the button. The injection takes about 10 seconds.

What happens if you miss a Zepbound dose? If you miss a dose and it's been less than 4 days since your scheduled injection day, take the missed dose as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your normal schedule. Do not double up.

Can you drink alcohol on Zepbound? Alcohol is not contraindicated, but it can worsen nausea and increase the risk of hypoglycemia if you're also taking diabetes medications. Moderate alcohol intake (1 to 2 drinks per occasion) is generally safe, but heavy drinking should be avoided.

Does Zepbound cause hair loss? Temporary hair shedding (telogen effluvium) occurs in about 3% to 5% of patients during rapid weight loss, regardless of the method. This is a response to caloric deficit and metabolic stress, not a direct effect of tirzepatide. Hair regrows once weight stabilizes.

How long do you stay on Zepbound? Zepbound is intended for long-term use. Clinical trials extended to 72 weeks, and extension studies are ongoing. Most patients regain weight if they discontinue the medication, so ongoing treatment is typically recommended to maintain weight loss.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is produced by compounding pharmacies rather than Eli Lilly. It's a medically appropriate alternative during the drug shortage but is not interchangeable with brand-name Zepbound.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Nature Medicine. 2024.
4. Wadden TA et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2024.
5. Lingvay I et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss: an indirect treatment comparison meta-analysis. Obesity Reviews. 2024.
6. Borner T et al. GIP and GLP-1 receptor agonism attenuates GIP-mediated food intake and reward-driven feeding via central mechanisms. Diabetes Care. 2023.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
8. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2021.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.